Up until the present, there have been no predictive biomarkers or indicators for guiding HNSCC treatment. A survey report on precision medicine entitled, “Global Precision Medicine Market : Analysis and Forecast, 2017–2026” from BIS Research registered $43.59 billion in 2016. It is estimated to reach $141.70 billion by 2026, with an annual growth rate of 11.23%. The Personalized Medicine Coalition for diagnostic and targeted agents was $25 billion in 2015.
“On a thumb rule, 30% of newly Cancer screened cases would account for HNSCC, the majority of men affected by it.”
Dr . . .
This exclusive content is reserved for our valued members. Kindly log in or sign up to enjoy full access and delve into the complete article.
